Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Free Cash Flow (2024 - 2026)

Kestra Medical Technologies (KMTS) reported Free Cash Flow of -$28.2 million for Q1 2026, down 222.49% year-over-year from $23.0 million in Q1 2025, and down 9.98% on a QoQ basis from -$25.6 million in Q4 2025.

Kestra Medical Technologies (KMTS) has 3 years of Free Cash Flow data on file, last reported at -$28.2 million in Q1 2026.

  • Quarterly Free Cash Flow fell 222.49% year-over-year to -$28.2 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was -$111.9 million (down 49.57% YoY) and the FY2025 annual result came in at -$79.5 million, up 5.89% from the prior year.
  • Free Cash Flow eased to -$28.2 million in Q1 2026 per KMTS's latest filing, from -$25.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$8.7 million in Q1 2025 and bottomed at -$34.4 million in Q3 2025.
  • The 3-year median for Free Cash Flow is -$24.1 million (2024), against an average of -$23.3 million.
  • The widest annual swing landed in 2025, when Free Cash Flow declined 13.8%; it then slumped 222.49% in 2026.
  • Tracing KMTS's Free Cash Flow over 3 years: stood at -$22.5 million in 2024, then fell by 13.8% to -$25.6 million in 2025, then declined by 9.98% to -$28.2 million in 2026.
  • Per Business Quant, the three latest KMTS Free Cash Flow figures stand at -$28.2 million (Q1 2026), -$25.6 million (Q4 2025), and -$34.4 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn 808.60 Mn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn 546.00 Mn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn 520.48 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn 63.80 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn -273.00 Mn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn 158.70 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn 120.26 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn 76.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn 53.30 Mn
10 Kestra Medical Technologies 1.13 Bn 840.05 Mn 12.91 Mn -28.16 Mn

Historic Data

Download Data 🔒
DateValue
Jan 31, 2026 -28.16 Mn
Jan 31, 2026 -28.16 Mn
Oct 31, 2025 -25.61 Mn
Oct 31, 2025 -25.61 Mn
Jul 31, 2025 -34.44 Mn
Jul 31, 2025 -34.44 Mn
Apr 30, 2025 -23.71 Mn
Apr 30, 2025 -23.71 Mn
Jan 31, 2025 -8.73 Mn
Jan 31, 2025 -8.73 Mn
Oct 31, 2024 -22.50 Mn
Oct 31, 2024 -22.50 Mn
Jul 31, 2024 -24.54 Mn
Jul 31, 2024 -24.54 Mn
Apr 30, 2024 -19.06 Mn
Apr 30, 2024 -19.06 Mn